1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Focal segmental glomerulosclerosis (FSGS) - Epidemiology Forecast - 2030

Focal segmental glomerulosclerosis (FSGS) - Epidemiology Forecast - 2030

  • April 2020
  • 83 pages
  • ID: 5885420
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Focal segmental glomerulosclerosis (FSGS)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the FSGS, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Focal segmental glomerulosclerosis (FSGS) Disease Understanding
Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed. The clinical features of FSGS are the features of nephrotic syndrome and include peripheral edema, marked proteinuria hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function. It may be found either as primary or secondary forms.
Primary FSGS sometimes has no identifiable cause or known etiology (idiopathic) and is linked to genetic mutations in podocyte-specific proteins, while secondary FSGS may occur in response to previous glomerular injury, glomerular hypertension, hypertrophy, drug toxicity, some malignancies or viral infections, obesity, and reduced renal mass.
FSGS is further classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion. The pathogenesis of FSGS is very complex; however, understanding basic mechanisms of podocyte injury is important not only for basic research but also for daily diagnostic pathology practice.

Focal segmental glomerulosclerosis (FSGS) Epidemiology
The FSGS epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted FSGS epidemiology segmented as the Total prevalence of FSGS, Gender-Specific cases of FSGS, and Clinical Subtype cases of FSGS. The report includes the prevalent scenario of FSGS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Focal segmental glomerulosclerosis (FSGS) Epidemiology
The epidemiology segment also provides the Focal segmental glomerulosclerosis (FSGS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total prevalent population of FSGS Associated in 7MM countries ranges from 202,687 in 2017.
• As per the estimates, the United States has the highest prevalent population of FSGS.
• Among the EU5 countries, Germany had the highest prevalent population of FSGS, followed by France. On the other hand, Spain had the lowest prevalent population with 12,805 cases in 2017.


Scope of the Report
• Focal segmental glomerulosclerosis (FSGS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• Focal segmental glomerulosclerosis (FSGS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Focal segmental glomerulosclerosis (FSGS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Focal segmental glomerulosclerosis (FSGS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of FSGS
• The report provides the segmentation of the Focal segmental glomerulosclerosis (FSGS) epidemiology by Prevalent Cases of Focal segmental glomerulosclerosis (FSGS) in 7MM
• The report provides the segmentation of the Focal segmental glomerulosclerosis (FSGS) epidemiology by gender-specific Prevalent Cases of Focal segmental glomerulosclerosis (FSGS) in 7MM
• The report provides the segmentation of the Focal segmental glomerulosclerosis (FSGS) epidemiology by clinical subtype based diagnosed Cases of Focal segmental glomerulosclerosis (FSGS) in 7MM


Report Highlights

• 11-Year Forecast of Focal segmental glomerulosclerosis (FSGS) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Focal segmental glomerulosclerosis (FSGS)
• Prevalent Cases according to segmentation: Gender-specific Prevalence of FSGS
• Prevalent Cases according to segmentation: Clinical- subtype-specific Prevalence of FSGS
• Diagnosed cases of FSGS

KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to FSGS?
• What are the key findings pertaining to the Focal segmental glomerulosclerosis (FSGS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Focal segmental glomerulosclerosis (FSGS) across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of the FSGS?
• What are the currently available treatments of FSGS?


Reasons to buy
The Focal segmental glomerulosclerosis (FSGS) Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Focal segmental glomerulosclerosis (FSGS) market
• Quantify patient populations in the global Focal segmental glomerulosclerosis (FSGS) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Focal segmental glomerulosclerosis (FSGS) therapeutics in each of the markets covered
• Understand the magnitude of Focal segmental glomerulosclerosis (FSGS) population by its Prevalence cases
• Understand the magnitude of Focal segmental glomerulosclerosis (FSGS) population by its Gender-specific cases
• Understand the magnitude of Focal segmental glomerulosclerosis (FSGS) population by its Clinical subtype-specific cases
• The Focal segmental glomerulosclerosis (FSGS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Focal segmental glomerulosclerosis (FSGS) Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
According to the United States, Renal Data Service (USRDS)-2005 documented data, it is reported that more than 7000 patients received ESRD therapy in the United States. The USRDS also demonstrates a dramatic increase in the incidence of ESRD due to FSGS, particularly over the last decade in the African American population.
Hull et al., reported that FSGS accounts for about 35% of cases of nephrotic syndrome in the US adults and 20–55% of cases in US children, with an estimated rate of 7 per 100,000.
Also, North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) shows that FSGS carries have the highest likelihood of progressing to end-stage renal disease (ESRD), exceeding the risk of hypoplasia, obstructive uropathy, and reflux nephropathy (from analysis of 6000 children with chronic kidney disease).
According to EMA, in 2018, FSGS was reported to affect around 2.6 per 10,000 people in European Union, which ensued to entitle FSGS as an orphan disease in Europe.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on